Healthcare
TransCode Therapeutics, Inc.(RNAZ)
Live Price
Offline$4.70
-12.15% today
1Y Change
-28.93%
Window
Jun 23, 2025 β Jun 12, 2026
- Market Cap
- $10.00M
- Revenue Growth
- 0.0%
- EPS Growth
- -11.6%
- Dividend Yield
- 0.0%
Coverage: 245 bars Β· Jun 23, 2025 β Jun 12, 2026
Research Briefing
A compact read on the setup, peer context, quarterly changes, and recent earnings reaction.
Research Snapshot
TransCode Therapeutics, Inc. (RNAZ) is a Healthcare stock with a market cap of $10.00M and listed on NASDAQ. The stock last traded around $4.70 and down 28.9% across the available one-year price window (Jun 23, 2025 β Jun 12, 2026). Baseline metrics include revenue growth of 0.0%, EPS growth of -11.6%, a dividend yield of 0.0%. What stands out right now is revenue 0.0%, EPS -11.6%, free cash flow -46.2% with operating margin 0.0% and ROIC -17.6%. Overall, the current profile looks closer to a turnaround or cyclical reset than a generic broad-market placeholder. Stock Foundry combines RNAZ price history, valuation, growth, dividend context, earnings, analyst forecasts, news, related Healthcare peers on this page.
Sector Context
How this name stacks up against nearby peers on first-pass metrics.
Revenue Growth
Below sector median
0.0% vs +7.6% peer median
Operating Margin
Below sector median
0.0% vs +19.4% peer median
What Changed This Quarter
Latest report context and the signals most likely to have changed the story.
Latest report is on the board
2026 was reported on May 18, 2026, but the surprise data is still limited.
The operating picture looks softer than before
Revenue is at 0.0% and EPS is at -11.6%, with operating margin around 0.0%.
Earnings Reaction Memory
How the stock has tended to move after recent reports.
Across the last 3 reported quarters, the stock averaged -6.8% over the next 5 trading days and finished higher after 0 of those reports.
View quarter-by-quarter reaction table
| Quarter | EPS Ξ | 1D | 5D | 20D |
|---|---|---|---|---|
2026 May 18, 2026 | β | +0.1% | -12.6% | β |
2026 Feb 25, 2026 | β | +1.9% | -1.4% | -14.4% |
2025 Nov 14, 2025 | +40.6% | +1.8% | -6.5% | -1.8% |
Benchmark Comparison
Normalized Performance vs SPY
Compare this ticker against a broad index, growth benchmark, or sector ETF using a shared 1Y normalization window.
RNAZ
β
Normalized return
SPY
β
S&P 500
Excess Return
β
Relative to SPY
RNAZ Max Drawdown
-67.30%
Trailing 1Y
SPY Max Drawdown
β
Trailing 1Y
Calendar-Year Returns
Uses the longest available daily history for RNAZ and SPY.
Company Overview
TransCode Therapeutics, Inc.
NASDAQ Capital Market
TransCode Therapeutics, Inc., a biopharmaceutical company, engages in the development and commercialization of drugs and diagnostics for treating and identifying metastatic disease. Its lead therapeutic candidate, TTX-MC138, is a preclinical stage product for the treatment of metastatic cancer. The company's products in preclinical programs include TTX-siPDL1, an siRNA-based modulator of programmed death-ligand 1; TTX-siLIN28B, an siRNA-based inhibitor of RNA-binding protein LIN28B. Its cancer agnostic programs comprise TTX-RIGA, an RNAΒbased agonist of the RIG-I-driven immune response in the tumor microenvironment; TTX-CRISPR, a CRISPR/Cas9Βbased therapy platform for the repair or elimination of cancer-causing genes inside tumor cells; and TTX-mRNA, an mRNA-based platform for the development of cancer vaccines meant to activate cytotoxic immune responses against tumor cells. The company was incorporated in 2016 and is based in Boston, Massachusetts.
- Leadership
- Philippe Calais
- IPO Date
- Jul 8, 2021
- Employees
- 7
- Street Address
- 6 Liberty Square
- Mailing
- Boston, MA, 02109
- Region
- Boston, MA, US
- Reporting Currency
- USD
- Investor Line
- 857-837-3099
- Last Updated
- May 4, 2026
Key Fundamentals
Valuation, growth, profitability, and balance sheet signals.
Valuation
- P/E
- β
- EV/EBITDA
- 0.3
- Price/Sales
- β
- Price/Book
- 0.7
Growth
- Revenue
- 0.0%
- EPS
- -11.6%
- Free Cash Flow
- -46.2%
Profitability
- Gross Margin
- 0.0%
- Operating Margin
- 0.0%
- Net Margin
- 0.0%
- ROE
- -491.6%
- ROIC
- -17.6%
Balance Sheet
- Debt/Equity
- β
- Current Ratio
- 6.29
Earnings Reports
Latest News
Official Releases
Company announcements and filings-style updates.
Next Step
Keep the research moving
After the overview, the strongest next step is usually chart context or a tighter compare set.